Publication date: Available online 17 November 2026 Source: The Journal of Pharmacology and Experimental Therapeutics Author(s): Jessica N. Wilson, Dora A. Mendez, Marisol Hernandez Garcia, Nikolay Shevchenko, Mark Mascal, Nicholas V. DiPatrizio, Rudy M. Ortiz
Pseudocannabinoid, H4CBD, Enhances Lipid Catabolism to Reduce Visceral Adiposity and Large Adipocyte Size in Advanced Metabolic Syndrome. // The Journal of Pharmacology and Experimental Therapeutics. – URL: https://www.sciencedirect.com/science/article/pii/S0022356526012711?dgcid=rss_sd_all
Pseudocannabinoid, H4CBD, Enhances Lipid Catabolism to Reduce Visceral Adiposity and Large Adipocyte Size in Advanced Metabolic Syndrome. The Journal of Pharmacology and Experimental Therapeutics. https://www.sciencedirect.com/science/article/pii/S0022356526012711?dgcid=rss_sd_all
“Pseudocannabinoid, H4CBD, Enhances Lipid Catabolism to Reduce Visceral Adiposity and Large Adipocyte Size in Advanced Metabolic Syndrome.” The Journal of Pharmacology and Experimental Therapeutics.
@article{article32393,
title = {Pseudocannabinoid, H4CBD, Enhances Lipid Catabolism to Reduce Visceral Adiposity and Large Adipocyte Size in Advanced Metabolic Syndrome},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
url = {https://www.sciencedirect.com/science/article/pii/S0022356526012711?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...